Daniel J. Booser
The University of Texas MD Anderson Cancer Center · 154 works · 11,220 citations · h-index 47
Top works
- Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
- Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer
- Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
- Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer
- Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks
- Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast Cancer
- SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer
- Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.
- Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma
- Management of Breast Cancer During Pregnancy Using a Standardized Protocol
- Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
- Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
- A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
- Combined Modality Treatment of Stage III and Inflammatory Breast Cancer
- Long-Term Results of Combined-Modality Therapy for Locally Advanced Breast Cancer With Ipsilateral Supraclavicular Metastases: The University of Texas M.D. Anderson Cancer Center Experience
- Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy
- Anthracycline Antibiotics in Cancer Therapy
- Canalicular stenosis secondary to docetaxel (taxotere)
- Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer
- Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma